Navigation Links
Avexa's Apricitabine Clinical Trial Update

MELBOURNE, Australia--(BUSINESS WIRE)--Jul 5, 2007 - Australian biotechnology company Avexa (ASX:AVX) announced today the completion of apricitabine's controlled, double blinded phase which represents the first 24 week segment of its Phase IIb trial. Patients have now progressed into the open-label section of the trial (weeks 24 to 48) and will continue to receive 800mg apricitabine twice a day as part of their daily treatment regime. The Company expects to release results from the 24 week blinded phase later this quarter.

Avexa also reported that apricitabine continues to maintain its excellent tolerability profile. To date, 14 patients have completed the full 48 weeks on the trial, and 13 of these have elected to continue on apricitabine treatment in an extension study. The longest treated patient has successfully completed more than 18 months of apricitabine therapy. One additional Serious Adverse Event (hospitalization for a minor surgical procedure) has been reported. However, like the three previously reported, this incident was not associated with study drug.

"This data clearly demonstrates that apricitabine is well tolerated in HIV patients. The number of patients requesting to enter the extension study after the 48 week trial to continue treatment with apricitabine is an indicator of the important role that apricitabine will play in the management of HIV. Apricitabine's clinical development remains on schedule and is demonstrating its potential as a safe and effective treatment for HIV," stated Dr. Julian Chick, CEO of Avexa.

Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of drugs for the treatment of infectious diseases, in particular diseases which have a significant unmet medical need. Avexa has dedicated resources and funding for key projects including antiviral drugs for HIV and an antibiotic alternative for antibiotic-resistant bact
'"/>




Page: 1 2

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Avexa Apricitabine Clinical Trial Update
(Date:7/30/2015)... OAKS, Calif., July 30, 2015  Amgen (NASDAQ: ... the second quarter of 2015. Key results include: ... the second quarter of 2014 to $5,370 million, ... by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable changes ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
(Date:7/30/2015)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... post-marketing commitment and submissions of data to regulatory ... Cancer Risk Characterization Study , a large (n= ... four European countries, for pioglitazone containing medicines, including ... of follow-up. Findings demonstrate that there is no ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6
... Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: ... survival studies that were conducted in Dr. William Scheld,s lab at ... treated with an siRNA against Senesco,s Factor 5A gene had a ... mice that received no treatment or a control siRNA.A total of ...
... speculation over what course the Swine Flu epidemic will ... ) last week analyzed the most recent peptide ... of the H1N1 virus will increase markedly, while its ... company,s quantitative analysis of the most recent sequence data ...
Cached Medicine Technology:Senesco Announces H1N1 Influenza Survival Test Results in Mice 2Senesco Announces H1N1 Influenza Survival Test Results in Mice 3Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data 2
(Date:7/30/2015)... ... 2015 , ... " DevExpress ” was featured on NewsWatch ... medium, and large businesses making an impact in their industry. Susan Bridges, a ... with viewers how DevExpress has provided software development tools that have helped app ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... 24/7 Care ... Angeles, Riverside, and San Bernardino, recently announced that the Centers for Medicare and Medicaid ... system of home health care providers. 24/7 Care At Home’s agency is one of ...
(Date:7/30/2015)... ... July 30, 2015 , ... The need for accessibility is never ... provide comfort to patients as well as visiting friends and family during these critical ... stations. , The stations - powered by ChargeItSpot , a Philadelphia-based startup that ...
(Date:7/30/2015)... ... 30, 2015 , ... OncLive®’s extensive roster of ... Comprehensive Cancer Center (JCCC) mutually agreed to collaborate on projects that promote ... marketing groups will help spread the news about the center’s leading-edge cancer research, ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zejax is a ... That Increases Training Capability , World renown body weight trainer, Paul Ziachik, ... ), that dramatically increases a person’s training capability. , The American College of ...
Breaking Medicine News(10 mins):Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 2Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 3Health News:UCLA Jonsson Comprehensive Cancer Center Teams with OncLive® as a Strategic Alliance Partner 4Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2
... and UNAIDS today issued new guidance on informed, voluntary ... with a view to significantly increasing access to needed ... ,The new guidance focuses on provider-initiated HIV ... in health facilities. ,Today, approximately 80 ...
... women, half of whom had breast cancer , has revealed ... risk of breast cancer. ,Douglas Easton at the ... was observed in one out of six women during the ... gene variant, in the gene called fibroblast growth factor receptor ...
... two certainties in life: "death and taxes." Joseph Dello Russo, ... for wearing reading glasses after forty, a condition doctors ... with a team of researches who in the past have ... are now hard at work with what may be a ...
... the University of Wisconsin-Madison have identified dozens of clues ... ,The researchers identified nearly 40 genes that, ... the parasite from forming an infection in the brains ... of promising targets for developing drugs that could block ...
... India. But they could also prove a huge embarrassment for ... Thirumurthy Nakka Boomaiah , 35 and hailing from Chennai, in ... has been sentenced to 69 days in prison in US ... and assaulting flight attendants. But he has already spent the ...
... patients will have a new -- virtually pain free ... Mercy Health System (SJMHS) announced today it will begin ... on Wednesday, June 6th. ,This advanced radiosurgery ... including previously inoperable tumors, with astounding accuracy and with ...
Cached Medicine News:Health News:WHO, UNAIDS Issue New Guidance on HIV Testing and Counseling 2Health News:Researchers Identify the Gene Mutation That Raises Breast Cancer Risk 2Health News:Cure for Reading Glasses? 2Health News:Mutant Parasites, Unable to Infect Hosts, Highlight Virulence Genes 2Health News:Indian Engineer Sentenced for Groping Women During Flight 2Health News:Advanced Cancer Treatment Brings New Hope to Michigan Patient 2
...
... System* was designed to provide ... range of prosthesis for a ... With the addition of the ... a more complete range of ...
...
... The only shoulder prosthesis with ... experience in thousands of patients. Ideal ... resulting in 3 or 4 part ... greater than 50%, head-splitting fractures, disabling ...
Medicine Products: